Fetroja Approved to Treat Complicated Urinary Tract Infections

Fetroja Approved to Treat Complicated Urinary Tract Infections
By: Womens Health Posted On: November 18, 2019 View: 132

Fetroja Approved to Treat Complicated Urinary Tract Infections

Latest Women's Health News

News Picture: Fetroja Approved to Treat Complicated Urinary Tract Infections

FRIDAY, Nov. 15, 2019 (HealthDay News) -- Antibacterial drug Fetroja (cefiderocol) has been approved to treat patients aged 18 years and older with complicated urinary tract infections (cUTIs), the U.S. Food and Drug Administration announced yesterday.

The drug is indicated for patients with limited or no alternative treatment options for cUTI, including kidney infections caused by susceptible Gram-negative microorganisms. Dosage is 2 g of Fetroja every eight hours administered by intravenous infusion over three hours. Dose adjustments are required based on creatinine clearance. Prescription labeling on Fetroja includes a warning for a higher all-cause mortality rate in Fetroja-treated critically ill patients with multidrug-resistant Gram-negative bacterial infections.

Approval of Fetroja was based on safety and efficacy data from 448 patients with cUTI in the APEKS-cUTI study. Symptoms resolved and bacteria were eradicated in 72.6 percent of patients who received Fetroja seven days after treatment completion versus 54.6 percent of patients who received imipenem/cilastatin. Clinical response rates were similar between the two groups of patients.

The cause of the higher mortality rate with Fetroja in critically ill patients with multidrug-resistant Gram-negative bacterial infections is unknown. According to the FDA, some of the deaths were due to worsening or complications of infection or underlying comorbidities. This higher mortality rate was also seen among patients treated for hospital-acquired/ventilator-associated pneumonia, bloodstream infections, or sepsis. The agency noted that the safety and efficacy of Fetroja for treating these types of infections has not been determined.

The most commonly reported adverse reactions with Fetroja included diarrhea, constipation, nausea, vomiting, elevations in liver tests, rash, infusion site reactions, candidiasis, cough, headache, and hypokalemia. Patients who have had severe hypersensitivity to beta-lactam antibacterial drugs should not take Fetroja.

Approval was granted to Shionogi & Co.

More Information

MedicalNews
Copyright © 2019 HealthDay. All rights reserved.

SLIDESHOW

Urinary Incontinence in Women: Types, Causes, and Treatments for Bladder Control See Slideshow

Let's block ads! (Why?)

  Contact Us
 DoUntoThem

24 hours

Tel : + (888) - 8XX XXX
Mail : support@dountothem.com

  Follow Us
  About

Welcome to DoUntoThem home of variety of news from all over the world.

Advertise With Us

Cookie Policy

Privacy Policy

Terms of Service